source
- Summit Therapeutics cancels $500 million secondary share offering citing market conditionsSummit Therapeutics announced it would pull a planned $500 million secondary share sale just one day after the announcement, saying market conditions were unfavorable. The offering had been slated…
- Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trialNovartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…